Cancer cells slow down the process of DNA replication to account for abnormal genomic features, possibly providing a target for future anti-cancer therapies
Bill Gates has revealed plans to personally invest $100 million in the Dementia Discovery Fund (DDF), with the hopes of finding new treatments.
Myriad Genetics plans to partner with the US Department of Veterans Affairs to assess the company’s GeneSight genetic test in veterans with depression.
French big Pharma, Sanofi has committed up to $805 million to license multiple sclerosis drug, PRN2246 from Principia Biopharma.
A more accurate test for Down’s Syndrome, Edwards and Patau syndromes has been developed by doctors, which could simplify screening processes.
Otonomy has reported a successful AVERTS-2 Phase III clinical trial of Otividex in patients with Meniere’s disease, after failure back in August.
The Government has appointed GlaxoSmithKline’s (GSK) president of research and development, as their new chief scientific advisor.
The Food and Drug Administration (FDA) approved Genentech’s Zelboraf as a treatment for patients diagnosed with a specific mutation of that disease.